Insights in the autoimmunity of myasthenia gravis.
Myasthenia gravis is a prototype anti-receptor autoimmune disease. Antibodies against proteins at the neuromuscular junction cause a defect in the signal transmission from nerve terminal to the damaged postsynaptic membrane. This issue of Autoimmunity reviews the mechanisms that lead to the destruction of the neuromuscular junction and the role of the thymus in myasthenia gravis and its animal models. In addition, this issue explores recent advances in diagnosis and treatment of this disease.
De Baets
Marc H
MH
Neuroimmunology Group, Department of Neuroscience, School of Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands. m.debaets@maastrichtuniversity.nl
D000818:Animals; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D015551:Autoimmunity; D006801:Humans; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D009469:Neuromuscular Junction / Q000276:immunology* / Q000503:physiopathology; D009435:Synaptic Transmission; D013950:Thymus Gland / Q000276:immunology
D001323:Autoantibodies